Supernus Pharmaceuticals Stock Today
| SUPN Stock | USD 37.31 0.74 2.02% |
Performance4 of 100
| Odds Of DistressLess than 6
|
Supernus Pharmaceuticals is selling at 37.31 as of the 3rd of December 2024; that is 2.02 percent increase since the beginning of the trading day. The stock's open price was 36.57. Supernus Pharmaceuticals has only a 6 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Supernus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2012 | Category Healthcare | Classification Health Care |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. The company has 55.22 M outstanding shares of which 6.52 M shares are at this time shorted by private and institutional investors with about 16.46 trading days to cover. More on Supernus Pharmaceuticals
Moving against Supernus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Supernus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Jack Khattar | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Trump Equities, Obamacare Repeal, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSupernus Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Supernus Pharmaceuticals' financial leverage. It provides some insight into what part of Supernus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals (SUPN) is traded on NASDAQ Exchange in USA. It is located in 9715 Key West Avenue, Rockville, MD, United States, 20850 and employs 652 people. Supernus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.08 B. Supernus Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 55.22 M outstanding shares of which 6.52 M shares are at this time shorted by private and institutional investors with about 16.46 trading days to cover.
Supernus Pharmaceuticals currently holds about 360.79 M in cash with 111.08 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.74.
Check Supernus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Supernus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Supernus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Supernus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Supernus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Supernus Ownership Details
Supernus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.5 M | |
| Gw&k Investment Management, Llc | 2024-09-30 | 1.2 M | |
| Aristotle Capital Boston, Llc | 2024-09-30 | 1.2 M | |
| American Century Companies Inc | 2024-09-30 | 1 M | |
| Goldman Sachs Group Inc | 2024-09-30 | 899.6 K | |
| Victory Capital Management Inc. | 2024-09-30 | 742.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 726.1 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 712.4 K | |
| Northern Trust Corp | 2024-09-30 | 606.3 K | |
| Blackrock Inc | 2024-06-30 | 10.4 M | |
| Vanguard Group Inc | 2024-09-30 | 6.1 M |
Supernus Pharmaceuticals Historical Income Statement
Supernus Stock Against Markets
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.